These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 9296058)
1. Ultrastructural changes in parasites induced by nanoparticle-bound pentamidine in a Leishmania major/mouse model. Fusai T; Boulard Y; Durand R; Paul M; Bories C; Rivollet D; Astier A; Houin R; Deniau M Parasite; 1997 Jun; 4(2):133-9. PubMed ID: 9296058 [TBL] [Abstract][Full Text] [Related]
2. Action of pentamidine-bound nanoparticles against Leishmania on an in vivo model. Fusai T; Deniau M; Durand R; Bories C; Paul M; Rivollet D; Astier A; Houin R Parasite; 1994 Dec; 1(4):319-24. PubMed ID: 9140499 [TBL] [Abstract][Full Text] [Related]
3. Activity of pentamidine-loaded poly (D,L-lactide) nanoparticles against Leishmania infantum in a murine model. Durand R; Paul M; Rivollet D; Fessi H; Houin R; Astier A; Deniau M Parasite; 1997 Dec; 4(4):331-6. PubMed ID: 9587601 [TBL] [Abstract][Full Text] [Related]
4. Physicochemical characteristics of pentamidine-loaded polymethacrylate nanoparticles: implication in the intracellular drug release in Leishmania major infected mice. Paul M; Durand R; Boulard Y; Fusaï T; Fernandez C; Rivollet D; Deniau M; Astier A J Drug Target; 1998; 5(6):481-90. PubMed ID: 9783679 [TBL] [Abstract][Full Text] [Related]
5. Activity of pentamidine-loaded methacrylate nanoparticles against Leishmania infantum in a mouse model. Durand R; Paul M; Rivollet D; Houin R; Astier A; Deniau M Int J Parasitol; 1997 Nov; 27(11):1361-7. PubMed ID: 9421724 [TBL] [Abstract][Full Text] [Related]
6. In vivo antileishmanial action of Ir-(COD)-pentamidine tetraphenylborate on Leishmania donovani and Leishmania major mouse models. Loiseau PM; Mbongo N; Bories C; Boulard Y; Craciunescu DG Parasite; 2000 Jun; 7(2):103-8. PubMed ID: 10887656 [TBL] [Abstract][Full Text] [Related]
7. [In vitro study of leishmanicidal agents with drug carriers]. Deniau M; Durand R; Bories C; Paul M; Astier A; Couvreur P; Houin R Ann Parasitol Hum Comp; 1993; 68(1):34-7. PubMed ID: 8494298 [TBL] [Abstract][Full Text] [Related]
8. Combined liposomal immuno- and chemotherapy of visceral leishmaniasis. Everlien H; Hockertz S Arzneimittelforschung; 1999 Nov; 49(11):954-61. PubMed ID: 10604050 [TBL] [Abstract][Full Text] [Related]
9. The activity and ultrastructural localization of primaquine-loaded poly (d,l-lactide) nanoparticles in Leishmania donovani infected mice. Rodrigues JM; Croft SL; Fessi H; Bories C; Devissaguet JP Trop Med Parasitol; 1994 Sep; 45(3):223-8. PubMed ID: 7899792 [TBL] [Abstract][Full Text] [Related]
10. Treatment of experimental visceral leishmaniasis in a T-cell-deficient host: response to amphotericin B and pentamidine. Murray HW; Hariprashad J; Fichtl RE Antimicrob Agents Chemother; 1993 Jul; 37(7):1504-5. PubMed ID: 8363382 [TBL] [Abstract][Full Text] [Related]
11. Oral pentamidine-loaded poly(d,l-lactic-co-glycolic) acid nanoparticles: an alternative approach for leishmaniasis treatment. Valle IV; Machado ME; Araújo CDCB; da Cunha-Junior EF; da Silva Pacheco J; Torres-Santos EC; da Silva LCRP; Cabral LM; do Carmo FA; Sathler PC Nanotechnology; 2019 Nov; 30(45):455102. PubMed ID: 31365912 [TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo activity of two Pt(IV) salts against leishmania donovani. Mesa-Valle CM; Rodriguez-Cabezas MN; Moraleda-Lindez V; Craciunescu D; Sanchez-Moreno M; Osuna A Pharmacology; 1998 Sep; 57(3):160-72. PubMed ID: 9691236 [TBL] [Abstract][Full Text] [Related]
13. In vitro study of the anti-leishmanial activity of biodegradable nanoparticles. Venier-Julienne MC; Vouldoukis I; Monjour L; Benoit JP J Drug Target; 1995; 3(1):23-9. PubMed ID: 7655817 [TBL] [Abstract][Full Text] [Related]
14. Pentamidine exerts in vitro and in vivo anti Trypanosoma cruzi activity and inhibits the polyamine transport in Trypanosoma cruzi. Díaz MV; Miranda MR; Campos-Estrada C; Reigada C; Maya JD; Pereira CA; López-Muñoz R Acta Trop; 2014 Jun; 134():1-9. PubMed ID: 24560964 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic evaluation of free and nanocapsule-encapsulated atovaquone in the treatment of murine visceral leishmaniasis. Cauchetier E; Paul M; Rivollet D; Fessi H; Astier A; Deniau M Ann Trop Med Parasitol; 2003 Apr; 97(3):259-68. PubMed ID: 12803857 [TBL] [Abstract][Full Text] [Related]
16. Co-administration of glycyrrhizic acid with the antileishmanial drug sodium antimony gluconate (SAG) cures SAG-resistant visceral leishmaniasis. Bhattacharjee A; Majumder S; Majumdar SB; Choudhuri SK; Roy S; Majumdar S Int J Antimicrob Agents; 2015 Mar; 45(3):268-77. PubMed ID: 25600891 [TBL] [Abstract][Full Text] [Related]
17. Novel Nanocarrier Platform for Effective Treatment of Visceral Leishmaniasis. Kannan S; Harel Y; Israel LL; Lellouche E; Varvak A; Tsubery MN; Lellouche JP; Michaeli S Bioconjug Chem; 2021 Nov; 32(11):2327-2341. PubMed ID: 34664934 [TBL] [Abstract][Full Text] [Related]
18. A randomized clinical trial of low dosage combination of pentamidine and allopurinol in the treatment of antimony unresponsive cases of visceral leishmaniasis. Das VN; Ranjan A; Sinha AN; Verma N; Lal CS; Gupta AK; Siddiqui NA; Kar SK J Assoc Physicians India; 2001 Jun; 49():609-13. PubMed ID: 11584934 [TBL] [Abstract][Full Text] [Related]